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Abstract
Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a
number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor
CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor
progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical
evaluation of Venetoclax and Daratumumab combination in the treatment of AML.
To the editor,
Acute Myeloid Leukemia (AML) is associated with poor
prognosis and high mortality causing around 85,000 global
deaths per year [1]. Current standard treatment for AML
is poorly tolerated and most therapy is not curative for pa-
tients. The intensive nature of proficient therapeutics for
AML are more suited towards younger patients, which is
not the typical age-group for this disease. This results in
limited effective treatment options, highlighting the need
for more targeted, well-tolerated treatments.
Recently numerous novel therapies have emerged for
treatment of AML. The BCL-2 family proteins are import-
ant in regulating intrinsic apoptotic processes [2]. Suppres-
sion of mitochondrial-mediated apoptosis by BCL-2
overexpression is a hallmark of AML progression, often
correlated with a poor response to cytotoxic treatment [3,
4]. Recently, clinical trials using BCL-2 inhibition by the
BH3 mimetic Venetoclax has been shown to be effective in
promoting caspase-dependent AML cell death [5], leading
to Venetoclax receiving FDA approval for treatment of
AML in combination with low dose cytarabine, decitabine
or the hypomethylating azacytidine [6]. This is an import-
ant milestone for AML treatment, as no curative therapies
have shown to be clinically effective at treating this disease.
Unfortunately, AML resistance to Venetoclax is com-
mon, therefore, numerous studies combining Venetoclax
with other therapies are being trialed [6, 7]. Our group
and others have reported CD38 is overexpressed in AML
and CD38 inhibition using Daratumumab is effective in
preclinical AML models [8, 9]. CD38 is a transmembrane
glycoprotein expressed on many hematopoietic cells [10].
In our recent study we demonstrated that Daratumumab
works by inhibiting mitochondrial transfer from mesen-
chymal stromal cell (MSC) to AML blasts in the bone
marrow (BM). Here we hypothesized that inhibiting the
CD38 using daratumumab, in combination with BCL-2
inhibition using Venetoclax, could be a strategy to im-
prove overall survival of AML patients.
To investigate BCL-2 inhibition in combination with
CD38 inhibition in AML we used primary AML blasts
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isolated from patients BM (Table 1). CD38 and BCL-2 ex-
pression on isolated AML and non-malignant control
CD34 cells were measured by flow cytometry (Fig. 1 a and
supplementary Figure 1). Cell viability was assessed using
various doses of Venetoclax or Daratumumab and showed
that 100nM Venetoclax alone inhibited AML cell viability
(Fig. 1b). Daratumumab alone had no effect on cell viabil-
ity at any concentration used (Fig. 1b). Furthermore, in
combination with Venetoclax, Daratumamab had no addi-
tive effect on AML survival (Fig. 1 c). Since AML is highly
reliant on the BM microenvironment, we used an in vitro
coculture system, AML was cultured with MSC with ei-
ther Venetoclax alone, Daratumumab alone, or Veneto-
clax and Daratumumab combination for 24 h. AML cells
were then stained with AnnexinV-FITC/PI and analyzed
using flow cytometry. Cells treated with Venetoclax and
Daratumumab combination had significantly higher apop-
tosis compared to untreated AML cells (Fig. 1d and e).
Treatment with Venetoclax or Daratumumab alone had
no significant effect on AML apoptosis when cultured
under these conditions, suggesting that these targeted
therapies are working through different pathways. To-
gether, these results highlight the need to study the effect-
iveness of Venetoclax and Daratumumab combination in
in vivo models of AML.
To do this we used a NOD.Cg-Prkdcscid
IL2rgtm1Wjl/SzJ (NSG) xenograft mouse model of AML
whereby on day 1 we transplanted 0.5 × 106 MV411 cells
or patient derived AML tagged with a luciferase con-
struct into the tail vein of NSG mice. On day 7 we ana-
lyzed NSG mice for AML engraftment. Mice were split
into treatment groups including vehicle control (PBS),
Table 1 AML diagnostic information
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Daratumumab alone on day 7 and 14 by intraperitoneal
injection (5 mg/kg), Venetoclax alone by oral gavage
(100 mg/kg/day) for 10 days or combination
Daratumumab (5 mg/kg) and Venetoclax (100 mg/kg/
day) (Fig. 2 a). The mice were then imaged using live
in vivo bioluminescence imaging on day 17 to determine
Fig. 1 Venetoclax and Daratumumab inhibit AML cell growth. a Primary AML and CD34 + flow cytometry analysis for CD38 and BCL-2 expression
as assessed by MFI (n = 7). b Primary AML (#1–6) were cultured together for 24 h in the presence of varying concentrations of Venetoclax alone
or Daratumumab alone. Cell viability was assessed by CellTiter-Glo (n = 6) and expressed as a percentage compared to control untreated cells.
c Primary AML were cultured together for 24 h in the presence of Venetoclax and varying concentrations of Daratumumab. Cell viability was
assessed by CellTiter-Glo (n = 3). d and e Primary AML (#1, #2, #3, #7 and #9) and MSC cultured together for 24 h in the presence of vehicle,
Venetoclax (100nm) alone or Daratumumab (100ng/ml) alone or Venetoclax and Daratumumab in combination. Primary AML were then stained
with Annexin V/PI, flow cytometry was used to detect cell death (n = 5). Statistical tests used were Mann-Whitney U test (A) or Kruskal-Wallis
statistical test followed by Dunn’s multiple comparisons (b-e). Data shown are means ± SD *P < 0.05 **P < 0.01
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Fig. 2 (See legend on next page.)
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tumor burden (Fig. 2b). The densitometry measurement
of treated animals and survival graphs confirmed com-
bination Daratumumab and Venetoclax was the most ef-
fective at reducing tumor burden (Fig. 2 c-f). Given the
heterogeneity of AML, one limitation of the study is that
only one AML patient sample and one cell line was used
in the in vivo experiments. Finally, in phase 1/2 clinical
trials in relapse/refractory myeloma combining Veneto-
clax with Daratumumab has a good safety profile [11].
Here, Venetoclax and Daratumumab combination
treatment resulted in a reduced leukemia growth in vitro
and in vivo. Our data opens a potential avenue for novel
Venetoclax drug combination with Daratumumab and
supports further clinical investigation as a therapeutic
approach in the treatment AML.
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